Lab
Guthrie Medical Group PC
Guthrie Medical Group PC was paid $2.94M by Medicaid between Jan 2018 and Dec 2024, across 85 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 22% of everything it billed.
33Billing provider infoGUTHRIE MEDICAL GROUP PC
SAYRE, PA 18840
SAYRE, PA 18840
33aNPI1649225855assigned 05/24/2006
33bProvider typeClinical Medical Laboratory
28Total paid$2.94M
24GClaims142,208
24DCodes billed85
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Pennsylvania
Rank by total paid#15 of 95
Median peer was paid$153K
This provider vs. median19×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SCOPELLITI, JOSEPH controls 15+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,515 | $83K | |
| 2019 | 5,999 | $68K | |
| 2020 | 9,762 | $126K | |
| 2021 | 22,696 | $581K | |
| 2022 | 33,407 | $875K | |
| 2023 | 33,831 | $634K | |
| 2024incomplete | 29,998 | $573K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 22% | 6,536 | 5,882 | $646K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 18% | 3,751 | 3,635 | $527K |
| 80053 | Comprehensive metabolic panel | 5.6% | 15,457 | 14,930 | $164K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 5.2% | 4,335 | 4,301 | $152K |
| 84443 | Thyroid stimulating hormone (TSH) | 4.5% | 7,851 | 7,741 | $132K |
| 80050 | General health panel | 4.3% | 2,242 | 2,222 | $128K |
| 80061 | Lipid panel | 3.5% | 8,591 | 8,540 | $104K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 3.5% | 624 | 606 | $102K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.6% | 2,758 | 2,718 | $76K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.6% | 2,740 | 2,700 | $75K |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.4% | 8,679 | 8,624 | $71K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.2% | 11,299 | 10,570 | $64K |
73 more codes
| 87631 | 1.6% | 362 | $48K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.6% | 5,321 | $46K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.3% | 3,628 | $39K |
| 87081 | 1.3% | 5,644 | $37K | |
| 85027 | 1.2% | 5,231 | $34K | |
| 84439 | 1.1% | 4,038 | $33K | |
| 82607 | 1.1% | 2,497 | $32K | |
| 87480 | 1.1% | 1,382 | $32K | |
| 87660 | 1.0% | 1,276 | $30K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,101 | $26K |
| 82746 | <1% | 2,104 | $23K | |
| 82728 | <1% | 1,807 | $22K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 419 | $19K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 583 | $17K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 290 | $17K |
| 86803 | <1% | 906 | $17K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 512 | $16K |
| 83970 | <1% | 407 | $16K | |
| 82043 | <1% | 2,172 | $14K | |
| 82570 | <1% | 2,331 | $13K | |
| 83540 | <1% | 1,758 | $13K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,485 | $12K |
| 87186 | <1% | 1,426 | $12K | |
| 83721 | <1% | 1,119 | $11K | |
| 86762 | <1% | 518 | $11K | |
| 87340 | <1% | 597 | $8K | |
| 87510 | <1% | 469 | $8K | |
| 83550 | <1% | 1,519 | $8K | |
| 84481 | <1% | 346 | $8K | |
| 83880 | <1% | 206 | $7K | |
| 86703 | <1% | 431 | $7K | |
| 83735 | <1% | 932 | $6K | |
| 86140 | <1% | 1,550 | $6K | |
| 83525 | <1% | 439 | $6K | |
| 86850 | <1% | 540 | $5K | |
| 85651 | <1% | 1,516 | $5K | |
| 84702 | <1% | 166 | $3K | |
| 84146 | <1% | 114 | $3K | |
| 84480 | <1% | 318 | $3K | |
| 86900 | <1% | 614 | $3K | |
| 83001 | <1% | 140 | $3K | |
| 85610 | <1% | 718 | $3K | |
| 86901 | <1% | 522 | $2K | |
| 87077 | <1% | 338 | $2K | |
| 81001 | <1% | 757 | $2K | |
| 86431 | <1% | 217 | $2K | |
| 82950 | <1% | 168 | $1K | |
| 81003 | <1% | 460 | $1K | |
| 80069 | <1% | 157 | $1K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 56 | $1K |
| 83690 | <1% | 168 | $978.95 | |
| 84703 | <1% | 67 | $692.15 | |
| 87205 | <1% | 136 | $650.29 | |
| 82274 | <1% | 94 | $646.70 | |
| 85652 | <1% | 232 | $616.56 | |
| 84550 | <1% | 78 | $433.64 | |
| 86376 | <1% | 32 | $337.81 | |
| 86800 | <1% | 15 | $299.51 | |
| 86618 | <1% | 12 | $297.95 | |
| 83002 | <1% | 13 | $275.52 | |
| 82550 | <1% | 43 | $247.93 | |
| 86704 | <1% | 13 | $234.01 | |
| 82248 | <1% | 33 | $230.96 | |
| 87070 | <1% | 27 | $223.12 | |
| 86308 | <1% | 25 | $200.82 | |
| 84134 | <1% | 12 | $180.85 | |
| 84153 | <1% | 13 | $148.63 | |
| 85378 | <1% | 12 | $136.68 | |
| 84156 | <1% | 30 | $117.73 | |
| 87147 | <1% | 26 | $102.25 | |
| 85007 | <1% | 17 | $47.49 | |
| 3046F | 0% | 12 | $0.00 | |
| 3044F | 0% | 628 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCOPELLITI, JOSEPH (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Guthrie Medical Group, P.C. | Sayre, PA | $82.19M |
| Vna Health System | Shamokin, PA | $192K |
| Gutharie Medical Group, P.C. | Sayre, PA | $156K |
| Guthrie Medical Group, P.C. | Corning, NY | $77K |
| Guthrie Medical Group, P.C. | Sayre, PA | $41K |
| Guthrie Medical Group, P.C. | Sayre, PA | $17K |
| Guthrie Medical Group, P.C. | Dushore, PA | $13K |
| Guthrie Medical Group, P.C. | Wellsboro, PA | $10K |
| Guthrie Medical Group, P.C. | Sayre, PA | $6K |
| Guthrie Medical Group, P.C. | Troy, PA | $5K |
| Guthrie Medical Group, P.C. | Sayre, PA | $3K |
| Guthrie Medical Group, P.C. | Sayre, PA | $3K |
| Guthrie Medical Group, P.C. | Towanda, PA | $2K |
| Guthrie Medical Group, P.C. | Sayre, PA | $1K |
| Guthrie Medical Group PC | Sayre, PA | $178.70 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.